CymaBay Therapeutics Inc (NASDAQ:CBAY)’s stock price rose 6.1% during mid-day trading on Friday . The company traded as high as $5.65 and last traded at $5.55, approximately 998,600 shares traded hands during mid-day trading. An increase of 17% from the average daily volume of 853,849 shares. The stock had previously closed at $5.23.
CBAY has been the topic of a number of research analyst reports. Evercore ISI reiterated a “buy” rating and issued a $15.00 target price on shares of CymaBay Therapeutics in a research note on Wednesday, August 14th. BidaskClub upgraded shares of CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 23rd. Cantor Fitzgerald set a $20.00 price target on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 18th. ValuEngine upgraded shares of CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 4th. Finally, Zacks Investment Research lowered shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $13.25.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.12 and a current ratio of 13.12. The company has a market capitalization of $376.48 million, a price-to-earnings ratio of -4.40 and a beta of 1.25. The firm’s 50-day simple moving average is $5.02 and its 200-day simple moving average is $7.03.
In other CymaBay Therapeutics news, CEO Sujal Shah acquired 5,000 shares of CymaBay Therapeutics stock in a transaction dated Monday, September 23rd. The stock was bought at an average cost of $5.53 per share, with a total value of $27,650.00. Following the acquisition, the chief executive officer now owns 111,900 shares of the company’s stock, valued at $618,807. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 11,900 shares of company stock valued at $59,600 over the last ninety days. 4.20% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC bought a new position in shares of CymaBay Therapeutics during the 3rd quarter worth about $61,000. SG Americas Securities LLC bought a new position in shares of CymaBay Therapeutics during the 3rd quarter worth about $85,000. Assenagon Asset Management S.A. bought a new position in shares of CymaBay Therapeutics during the 3rd quarter worth about $1,037,000. University of Notre Dame DU Lac bought a new position in shares of CymaBay Therapeutics during the 2nd quarter worth about $2,043,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of CymaBay Therapeutics during the 2nd quarter worth about $80,000. 99.49% of the stock is owned by institutional investors.
CymaBay Therapeutics Company Profile (NASDAQ:CBAY)
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: Key terms to understand channel trading
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.